Empirical evidence of neuroprotection by dual cholinesterase inhibition in Alzheimer's disease

NeuroReport

Volumn 16, Issue 2, 2005, Pages 107-110

  Venneri, Annalena ^a   McGeown, William J ^a   Shanks, Michael F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

Alzheimer's disease; Cholinesterase inhibitors; Dementia; Disease progression; Donepezil; Galantamine; Grey matter; MRI; Neuroimaging; Rivastigmine; Treatment

Indexed keywords

CHOLINESTERASE; CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; RIVASTIGMINE;

AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN ATROPHY; CHOLINESTERASE INHIBITION; CLINICAL ARTICLE; DOSE RESPONSE; GRAY MATTER; HUMAN; NEUROIMAGING; NEUROPROTECTION; PRIORITY JOURNAL; SIDE EFFECT;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANALYSIS OF VARIANCE; BRAIN; BUTYRYLCHOLINESTERASE; CHOLINESTERASE INHIBITORS; EMPIRICAL RESEARCH; HUMANS; NEUROPROTECTIVE AGENTS;

EID: 13844251864     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200502080-00006     Document Type: Article

References (13)

1. Neuropathology Group of the Medical Research Council Cognitive Function and Ageing Study (MRC CFAS). Pathological correlates of late-onset dementia in a multicentre, community-based population in England and Wales. Lancet 2001; 357:169-175.
2. Whalley LJ. Brain ageing and dementia: what makes the difference? Br J Psychiatry 2002; 181:369-371.
3. Fox NC and Schott JM. Imaging cerebral atrophy: normal ageing to Alzheimer's disease. Lancet 2004; 363:392-394.
4. Mesulam MM and Geula C. Butyrylcholinesterase reactivity differentiates the amyloid plaques of aging from those of dementia. Ann Neurol 1994; 36:722-727.
5. Guillozet AL, Smiley JF, Mash DC and Mesulam MM. Butyryl-cholinesterase in the life cycle of amyloid plaques. Ann Neurol 1997; 42:909-918.
6. McKhann G, Drachman D, Folstein M, Katzman R, Price D and Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDA-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944.
7. Silbert LC, Quinn JF, Moore MM, Corbridge E, Ball MJ, Murdoch G et al. Changes in premorbid brain volume predict Alzheimer's disease pathology. Neurology 2003; 61:487-492.
8. Oddo S, Billings L, Kesslak JP, Cribbs DH and LaFerla FM. Aβ immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron 2004; 43:321-332.
9. Alexander GE, Chen K, Pietrini P, Rapoport SI and Reiman EM. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am J Psychiatry 2002; 159:738-745.
10. Venneri A, Shanks MF, Staff RT, Pestell SJ, Forbes KE et al. Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer's disease. Neuroreport 2002; 13:83-87.
11. Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003; 65:193-207.
12. Testa C, Laakso MP, Sabattoli F, Rossi R, Beltramello A, Soininen H and Frisoni GB. A comparison between the accuracy of voxel-based morphometry and hippocampal volumetry in Alzheimer's disease. J Magn Reson Imaging 2004; 19:274-282.
13. Nestor PJ, Scheltens P and Hodges JR. Advances in the early detection of Alzheimer's disease. Nature Rev Neurosci 2004; Suppl:S34-S41.